Revance Therapeutics Current Assets

Revance Therapeutics's current assets stands at $330M as of September 2024. That compares with $390M in the prior-year period — down 15.1% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Revance Therapeutics reported $330M in current assets versus $390M a year earlier — a 15.1% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $390M in the prior-year period — down 15.1% year over year. Sustained growth in current assets can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Revance Therapeutics's current assets evolved across reporting periods, while the comparison chart places RVNC next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, current assets is commonly used to spot outliers. Revance Therapeutics's reading of $330M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.